| [1］Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR).OPTN/SRTR 2010 Annual Data Report［R］.Rockville，MD：Department of Health and Human Services，Health Resources and Services Administration，Healthcare Systems Bureau，Division of Transplantation，2011. [2］Wolfe RA，Ashby VB，Milford EL，et al.Comparison of mortality in all patients on dialysis，patients on dialysis awaiting transplantation，and recipients of a first cadaveric transplant［J］.New Engl J Med，1999，341(23)：1725-1730. [3］Rao PS，Merion RM，Ashby VB，et al.Renal transplantation in elderly patients older than 70 years of age：results from the Scientific Registry of Transplant Recipients［J］.Transplantation，2007，83(8)：1069-1074. [4］Jassal SV，Opelz G，Cole E.Transplantation in the elderly：a review［J］.Geriatric nephrology and urology，1997，7(3)：157-165. [5］Debska-Sslizien A，Jankowska MM，Wolyniec W，et al.A single-center experience of renal transplantation in elderly patients：a paired-kidney analysis［J］.Transplantation，2007，83(9)：1188-1192. [6］Kidney Disease：Improving Global Outcomes (KDIGO) Transplant Work Group.KDIGO clinical practice guideline for the care of kidney transplant recipients［J］.Am J Transplant,2009，9(Suppl 3)：S1-S157. [7］McKay D，Jameson J.Kidney transplantation and the ageing immune system［J］.Nat Rev Nephrol，2012，8(12)：700-708. [8］Webster AC，Craig JC，Simpson JM，et al.Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation：a cohort study of 15，183 recipients［J］.Am J Transplant，2007，7(9)：2140-2151. [9］Schena FP，Pascoe MD，Alberu J，et al.Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients：24-month efficacy and safety results from the CONVERT trial［J］.Transplantation，2009，87(2)：233-242. [10］Tsaur I，Jones J，Melamed RJ，et al.Postoperative voiding dysfunction in older male renal transplant recipients［J］.Transpl P，2009，41(5)：1615-1618. [11］Gill J，Bunnapradist S，Danovitch GM，et al.Outcomes of kidney transplantation from older living donors to older recipients［J］.Am J Kidney Dis，2008，52(3)：541-552. [12］Merion RM，Ashby VB，Wolfe RA，et al.Deceased-donor characteristics and the survival benefit of kidney transplantation［J］.JAMA，2005，294(21)：2726-2733. [13］Tullius SG，Milford E.Kidney allocation and the aging immune response［J］.New Engl J Med，2011，364(14)：1369-1370. [14］Gill J，Sampaio M，Gill JS，et al.Induction immunosuppressive therapy in the elderly kidney transplant recipient in the United States.Clin J Am Soc Nephro，2011，6(5)：1168-1178. [15］Lopez-Hoyos M，Rodrigo E，Arias M.The usefulness of intracellular adenosine-5′-triphosphate measurement in CD4+ cells in renal transplant［J］.Nefrologia，2013，33(3)：381-388. [16］Jacobson PA，Schladt D，Oetting WS，et al.Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs［J］.AM j Transplant，2012，12(12)：3326-3336. [17］Murray B，Hawes E，Lee RA，et al.Genes and beans：pharmacogenomics of renal transplant.Pharmacogenomics，2013，14(7)：783-798. |
